Literature DB >> 24257807

Impact of repeated intravenous bone marrow mesenchymal stem cells infusion on myocardial collagen network remodeling in a rat model of doxorubicin-induced dilated cardiomyopathy.

Qin Yu1, Qianxiao Li, Rongmei Na, Xiaofei Li, Baiting Liu, Lili Meng, Hanyu Liutong, Weiyi Fang, Ning Zhu, Xiaoqun Zheng.   

Abstract

Bone marrow mesenchymal stem cells (MSCs) transplantation improved cardiac function and reduced myocardial fibrosis in both ischemic and non-ischemic cardiomyopathies. We evaluated the effects of repeated peripheral vein injection of MSCs on collagen network remodeling and myocardial TGF-β1, AT1, CYP11B2 (aldosterone synthase) gene expressions in a rat model of doxorubicin (DOX)-induced dilated cardiomyopathy (DCM). Thirty-eight out of 53 SD rats survived at 10 weeks post-DOX injection (2.5 mg/kg/week for 6 weeks, i.p.) were divided into DCM blank (without treatment, n = 12), DCM placebo (intravenous tail injection of 0.5 mL serum-free culture medium every other day for ten times, n = 13), and DCM plus MSCs group (intravenous tail injection of 5 × 10(6) MSCs dissolved in 0.5 mL serum-free culture medium every other day for 10 times, n = 13). Ten untreated rats served as normal controls. At 20 weeks after DOX injection, echocardiography, myocardial collagen content, myocardial expressions of types I and III collagen, TGF-β1, AT1, and CYP11B2 were compared among groups. At 20 weeks post-DOX injection, 8 rats (67%) survived in DCM blank group, 9 rats (69%) survived in DCM placebo group while 13 rats (100 %) survived in DCM plus MSCs group. Left ventricular end-diastolic diameter was significantly higher and ejection fraction was significantly lower in DCM blank and DCM placebo groups compared to normal control rats, which were significantly improved in DCM plus MSCs group (all p < 0.05 vs. DCM blank and DCM placebo groups). Moreover, myocardial collagen volume fraction, types I and III collagen, myocardial mRNA expressions of TGF-β1, AT1, CYP11B2, and collagen I/III ratio were all significantly lower in DCM plus MSCs group compared to DCM blank and DCM placebo groups (all p < 0.05). Repeated intravenous MSCs transplantation could improve cardiac function by attenuating myocardial collagen network remodeling possibly through downregulating renin-angiotensin-aldosterone system in DOX-induced DCM rats.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24257807     DOI: 10.1007/s11010-013-1894-1

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  27 in total

1.  Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart.

Authors:  Mamoru Satoh; Motoyuki Nakamura; Hidenori Saitoh; Hidetoshi Satoh; Tomonari Akatsu; Junji Iwasaka; Tomoyuki Masuda; Katsuhiko Hiramori
Journal:  Clin Sci (Lond)       Date:  2002-04       Impact factor: 6.124

2.  Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation.

Authors:  Jin H Li; Hong-Jian Zhu; Xiao R Huang; Kar N Lai; Richard J Johnson; Hui Y Lan
Journal:  J Am Soc Nephrol       Date:  2002-06       Impact factor: 10.121

Review 3.  Mesenchymal stem cells engineered for cancer therapy.

Authors:  Khalid Shah
Journal:  Adv Drug Deliv Rev       Date:  2011-06-29       Impact factor: 15.470

4.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.

Authors:  John J V McMurray; Stamatis Adamopoulos; Stefan D Anker; Angelo Auricchio; Michael Böhm; Kenneth Dickstein; Volkmar Falk; Gerasimos Filippatos; Cândida Fonseca; Miguel Angel Gomez-Sanchez; Tiny Jaarsma; Lars Køber; Gregory Y H Lip; Aldo Pietro Maggioni; Alexander Parkhomenko; Burkert M Pieske; Bogdan A Popescu; Per K Rønnevik; Frans H Rutten; Juerg Schwitter; Petar Seferovic; Janina Stepinska; Pedro T Trindade; Adriaan A Voors; Faiez Zannad; Andreas Zeiher
Journal:  Eur Heart J       Date:  2012-05-19       Impact factor: 29.983

Review 5.  Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease.

Authors:  Adam R Williams; Joshua M Hare
Journal:  Circ Res       Date:  2011-09-30       Impact factor: 17.367

6.  Calcineurin mediates the angiotensin II-induced aldosterone synthesis in the adrenal glands by up-regulation of transcription of the CYP11B2 gene.

Authors:  Toshiyuki Yamashiro; Hideaki Kuge; Jin Zhang; Koichi Honke
Journal:  J Biochem       Date:  2010-04-22       Impact factor: 3.387

7.  Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.

Authors:  Sameer Stas; Adam Whaley-Connell; Javad Habibi; Lama Appesh; Melvin R Hayden; Poorna R Karuparthi; Mahnaz Qazi; E Matthew Morris; Shawna A Cooper; C Daniel Link; Craig Stump; Meredith Hay; Carlos Ferrario; James R Sowers
Journal:  Endocrinology       Date:  2007-05-10       Impact factor: 4.736

Review 8.  Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.

Authors:  K T Weber; C G Brilla
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

9.  Mesenchymal stem cells and cardiovascular disease: a bench to bedside roadmap.

Authors:  Manuel Mazo; Miriam Araña; Beatriz Pelacho; Felipe Prosper
Journal:  Stem Cells Int       Date:  2012-01-22       Impact factor: 5.443

10.  Does pretreatment of bone marrow mesenchymal stem cells with 5-azacytidine or double intravenous infusion improve their therapeutic potential for dilated cardiomyopathy?

Authors:  Sirui Yang; Jinhua Piao; Lianhua Jin; Yan Zhou
Journal:  Med Sci Monit Basic Res       Date:  2013-01-14
View more
  23 in total

Review 1.  The Therapeutic Potential of Mesenchymal Stromal Cells in the Treatment of Chemotherapy-Induced Tissue Damage.

Authors:  Alexander Rühle; Ramon Lopez Perez; Bingwen Zou; Anca-Ligia Grosu; Peter E Huber; Nils H Nicolay
Journal:  Stem Cell Rev Rep       Date:  2019-06       Impact factor: 5.739

Review 2.  The emerging therapeutic role of mesenchymal stem cells in anthracycline-induced cardiotoxicity.

Authors:  Huanrong Lan; Qi Xue; Yuyao Liu; Ketao Jin; Xingliang Fang; Hong Shao
Journal:  Cell Tissue Res       Date:  2021-01-12       Impact factor: 5.249

3.  Structural remodeling of the heart and its premotor cardioinhibitory vagal neurons following T(5) spinal cord transection.

Authors:  Heidi L Lujan; Hussein Janbaih; Stephen E DiCarlo
Journal:  J Appl Physiol (1985)       Date:  2014-03-07

Review 4.  Mechanisms supporting potential use of bone marrow-derived mesenchymal stem cells in psychocardiology.

Authors:  Jianyang Liu; Lijun Zhang; Meiyan Liu
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

5.  Mesenchymal stem cells confer resistance to doxorubicin-induced cardiac senescence by inhibiting microRNA-34a.

Authors:  Wenzheng Xia; Meng Hou
Journal:  Oncol Lett       Date:  2018-04-23       Impact factor: 2.967

Review 6.  New Paradigms in Cell Therapy: Repeated Dosing, Intravenous Delivery, Immunomodulatory Actions, and New Cell Types.

Authors:  Marcin Wysoczynski; Abdur Khan; Roberto Bolli
Journal:  Circ Res       Date:  2018-07-06       Impact factor: 17.367

7.  Effects of PPARα/PGC-1α on the myocardial energy metabolism during heart failure in the doxorubicin induced dilated cardiomyopathy in mice.

Authors:  Yongyao Yang; Hongming Zhang; Xiaoyan Li; Tianhe Yang; Qingan Jiang
Journal:  Int J Clin Exp Med       Date:  2014-09-15

8.  Hydrogen sulfide ameliorates doxorubicin‑induced myocardial fibrosis in rats via the PI3K/AKT/mTOR pathway.

Authors:  Liangui Nie; Maojun Liu; Jian Chen; Qian Wu; Yaling Li; Jiali Yi; Xia Zheng; Jingjing Zhang; Chun Chu; Jun Yang
Journal:  Mol Med Rep       Date:  2021-03-02       Impact factor: 2.952

Review 9.  Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears.

Authors:  Fernando Ezquer; Jaime Gutiérrez; Marcelo Ezquer; Christian Caglevic; Helio C Salgado; Sebastián D Calligaris
Journal:  Stem Cell Res Ther       Date:  2015-06-24       Impact factor: 6.832

Review 10.  The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy.

Authors:  Xianyun Wang; Jun Zhang; Fan Zhang; Jing Li; Yaqi Li; Zirui Tan; Jie Hu; Yixin Qi; Quanhai Li; Baoyong Yan
Journal:  Stem Cells Int       Date:  2015-05-26       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.